NCT00239681

URI: https://gptkb.org/entity/NCT00239681
GPTKB entity
Statements (27)
Predicate Object
gptkbp:instanceOf gptkb:clinical_trial
gptkbp:ageRange 18 years and older
gptkbp:allocates Randomized
gptkbp:clinicalTrials.govIdentifier gptkb:NCT00239681
gptkbp:completedIn December 2006
gptkbp:condition gptkb:Metastatic_Breast_Cancer
gptkbp:eligibility Women with HER2-positive metastatic breast cancer who have received prior therapy including an anthracycline, a taxane, and trastuzumab
gptkbp:enrollment 399
gptkbp:gender Female
https://www.w3.org/2000/01/rdf-schema#label NCT00239681
gptkbp:intervention gptkb:Capecitabine
gptkb:Lapatinib
gptkbp:location gptkb:Asia
gptkb:Europe
gptkb:United_States
gptkbp:mask None (Open Label)
gptkbp:period Phase 3
gptkbp:primaryCompletionDate December 2006
gptkbp:result Time to progression
gptkbp:secondaryOutcome Overall survival
Response rate
gptkbp:sponsor GlaxoSmithKline
gptkbp:startDate October 2005
gptkbp:studyType Interventional
gptkbp:title gptkb:A_Study_of_the_Safety_and_Efficacy_of_Lapatinib_in_Combination_With_Capecitabine_in_Women_With_Metastatic_Breast_Cancer
gptkbp:bfsParent gptkb:JUPITER_trial
gptkbp:bfsLayer 6